Heredodejeneratif Hastalıklarda Tedavi Seçenekleri
Özet
Heredodejeneratif hastalıkların yönetiminde temel hedef, hızlı tanı ile gecikmelerin önlenmesi ve hastaların yaşam kalitesini artırmaktır. Tedavi süreçleri, semptomatik destek sağlayan genel yaklaşımlar ile kök hücre nakli ve gen tedavisi gibi hastalığa özgü spesifik yöntemler olarak iki ana başlıkta ele alınmaktadır. Birçok lökodistrofi türünde kesin tedavi bulunmadığından; beslenme rehabilitasyonu, fizyoterapi ve nörolojik komplikasyonların yönetimi gibi destekleyici uygulamalar büyük önem taşımaktadır. Erken dönemde yapılan teşhis ve doğru tedavi seçimi, hastalığın ilerleyişini yavaşlatarak morbiditeyi azaltmada kritik bir rol oynamaktadır.
The primary goal in managing heredodegenerative diseases is to prevent diagnostic delays and improve the overall quality of life for patients. Treatment strategies are categorized into general approaches, focusing on symptomatic support like nutrition and physical therapy, and disease-specific interventions such as stem cell transplantation or gene therapy. Since curative options remain unavailable for many leukodystrophies, the comprehensive management of neurological and physical complications is essential. Early identification and targeted therapeutic choices play a critical role in slowing disease progression and reducing patient morbidity.
Referanslar
Parikh S, Bernard G, Leventer RJ et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephalopathies. Molecular Genetics and Metabolism. 2015; 114:501-515.
Ashrafi MR, Amanat M, Garshasbi M et al. An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies. Expert Review of Neurotherapeutics. 2020; 20(1):65-84.
Adang LA, Sherbini O, Ball L, et al. Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. Mol Genet Metab.2017;122:18-32.
Tetsuhide Ito , Robert T Jensen. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448-57.
Larry Holmes , Maria Julia Cornes, Beatrix Foldi, Freeman Miller, Kirk Dabney. Clinical epidemiologic characterization of orthopaedic and neurological manifestations in children with leukodystrophies. J Pediatr Orthop. 2011;31(5):587-93.
Keller SR, Mallack EJ, Rubin JP, et al. Practical approaches and knowledge gaps in the care for children with leukodystrophies. J Child Neurol. 2021;36:65-78.
Van der Knaap MS, Schiffmann R, Mochel F, Wolf N. Diagnosis prognosis and treatment of leukodystrophies.Lancet Neurol 2019;18(10):962-972.
Page KM, Stenger EO, Connelly JA, Shyr D, West T, Wood S. Hematopoetic Stem Cell Transplantation to Treat Leukodystrophies: Clinical Practice Guidelines from the Hunter’s Hope Leukodystrophy Care Network. Biol Blood Marrow Transplant. 2019;25(12):e363-e374.
Amy T, Waldman MD. Leucodystrophies. Continuum 2018;24(1, Child Neurology):130-149
Gupta N, Henry RG, Kang SM, et al. Long-term safety, immunologic response, and imaging outcomes following neural stem cell transplantation for pelizaeus-merzbacher disease. Stem Cell Reports. 2019;13:254-261.
Leone P, Shera D, McPhee SW,et al. Long-term follow up after gene therapy for Canavan disease. Sci Transl Med. 2012;4(165):165ra163-165ra163.
Rosenberg JB, Kaminsky SM, Aubourg P, Crystal RG, Sondhi D. Gene Therapy for Metachromatic Leukodystrophy. Journal of Neuroscience Research. 2016; 94:1169-1179.
Van der Knaap M, Bugiani M. Leukodystrophies:a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017; 134(3):351-382.
Rutherford HA, Hamilton N. Animal models of leukodystrophy: a new perspective fort he development of therapies. The FEBS J. 2019; 286(21):4176-4191.
Bradbury AM, Ream MA. Recent Advancements in the Diagnosis and Treatment of Leukodystrophies. Semin Pediatr Neurol. 2021;37:100876.
Kohlschütter A, Schulz A, Bartsch U, Storch S. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses. CNS Drugs. 2019; 33(4): 315–325.
Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378:1898–1907. doi: 10.1056/NEJMoa1712649.
Braga-Neto P, Pedroso JL, Kuo SH, et al. Current concepts in the treatment of hereditary ataxias. Arq Neuropsiquiatr. 2016 Mar; 74(3): 244–252.
Socha P , Janczyk W, Dhawan A, et al. Wilson’s Disease in Children: A Position Paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018 Feb;66(2):334-344.doi: 10.1097/MPG.0000000000001787.
Klopstock T, Tricta F, Neumayr L, Karin I, Zorzi G, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol. 2019 Jul;18(7):631-642. doi: 10.1016/S1474-4422(19)30142-5.
